385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment.

Transplantation and Cellular Therapy

Timothy S. Olson, Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson. 385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment. Transplantation and Cellular Therapy. 2023 Feb 1; 29(2):s291-s292.

2023

https://researcherprofiles.org/profile/420600614

Northern California Comprehensive Thalassemia Center

Search form

You are here

385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment.